Daratumumab can cause erratic false positives in the blood antibody screen and crossmatch obtained prior to a transfusion. Does this phenomenon occur with other monoclonal antibodies? —Name withheld on request
The issues with blood crossmatch are due to daratumumab’s effects on CD-38, which is also expressed on red blood cells; therefore, the phenomenon is not expected to occur with other monoclonal antibodies currently on the market that do not bind to CD-38 receptors on red blood cells.
